Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 680 participants.
Also called NCT07746882
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 680 participants
- Registry
-
NCT07746882
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07746882. Randomized; double masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2028-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
- Condition
- Stroke
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Record details
- Record id
cardio:ct-nct07746882- Content hash
e220748d4958ede3e433ab9cda81157b67ef8ab74838d2eb11a7484eaef9c849